B. Riley raised the firm’s price target on Cytokinetics to $122 from $66 and keeps a Buy rating on the shares. The analyst cites heightened conviction in aficamten taking a dominant market share in the cardiac myosin inhibitor market following the “strong” Phase III SEQUIOA-HCM data disclosures for the target increase.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYTK:
- Liquidia added to Conviction Buy, named 2024 Top Pick at Needham
- Cytokinetics downgraded to Equal Weight from Overweight at Morgan Stanley
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- The biotech stocks to own in 2024, according to Piper Sandler